PACK IN HAND · ONE-PAGE CHECK
Medicine pack check sheet
Print this sheet or fill it in before speaking with a pharmacist or clinician. Copy only what is printed on the pack in hand. The published fields below are starting points from this record, not proof that your pack is the same product.
Entries stay only in this open page and are not saved or sent.
Published record starting point
- Record display name
- LIALDA
- Generic name / active ingredient
- mesalamine delayed-release tablets
- Dosage-form class
- LIALDA is a mesalamine delayed-release tablet whose coat begins to break down at about pH 6.8 or above, followed by extended release. ASACOL HD, PENTASA, APRISO, DELZICOL, suppositories, enemas and products from different manufacturers are separate exact products and cannot be self-interchanged by a shared ingredient or total milligrams.
- Route
- Oral
- Record reviewed
- 2026-09-05
Copy from the pack in hand
Source-linked reading points
- Kidney function requires professional assessment before and during treatment. Prior kidney disease, older age, dehydration or concurrent nephrotoxic medicines needs extra review. Marked urine change, swelling or severe illness needs prompt care; do not self-stop or switch.
- NSAIDs and other nephrotoxic medicines may increase renal adverse-reaction risk. Do not merely separate them using a webpage; give prescriptions, OTC pain medicines, herbs and supplements together to a doctor or pharmacist.
- Azathioprine or 6-mercaptopurine may increase blood-dyscrasia risk and requires professional review of complete blood counts and platelets. Fever, unusual bruising, bleeding or marked fatigue cannot be self-assessed on a webpage.
- The label reports a higher incidence of blood dyscrasias in people aged 65 and older. Kidney change and polypharmacy are also common; review actual packs, prescriptions and tests together rather than self-reducing by age.
Reviewed presentation examples — compare every field
- Mesalamine 1.2 g per tablet; 120-tablet bottleNDC 54092-476-12